SynAct Pharma AB holds investor meetings in connection with the rights issue

Today, 19th April 2018, sees the beginning of the subscription period for SynAct Pharma AB’s (“SynAct”) rights issue of approximately SEK 22.4 million before issue costs. The subscription period runs until 8th May 2018. In connection with the rights issue, the company will participate in investor meetings to present its business and future plans. Investor meetings are free to attend and light refreshments are offered.

See below for more information about the meetings and application. More information about the rights issue is available on the company’s (www.synactpharma.com), AktieTorget’s (www.aktietorget.se) and Sedermera FondKommission’s (www.sedermera.se) respective websites .

18th April 2018 – Malmo

Investor lunch with Sedermera Fondkommission
Börshuset
Skeppsbron 2, Malmo
at 11.30am – 1.00pm

Application via www.sedermera.se

23rd April 2018 – Stockholm

Investor meeting
Scandic Anglais
Humlegårdsgatan 23, Stockholm, Sweden
at 8.30pm – 9.00pm

Application via www.sedermera.se

24th April 2018 – Gothenburg

Investor lunch with Sedermera Fondkommission
Clarion Hotel Post
Drottningtorget 10
at 11.30am – 1.00pm

Application via www.sedermera.se

3 May 2018 – Stockholm

Share Day in Stockholm
Operaterassen
Karl XII:s torg
at 11.30am – 12.15pm

Application via www.aktiespararna.se

Financial advisor

Sedermera Fondkommission is the financial advisor to SynAct Pharma in connection with the rights issue.

For questions regarding the rights issue, please contact:

Sedermera Fondkommission
Tel. + 46 (0) 40 615 14 10
e-mail: info@sedermera.se

For further information about SynAct Pharma AB, please contact:

Jeppe Øvlesen                                                                                         Thomas Jonassen

CEO, SynAct Pharma AB                                                                   CSO, SynAct Pharma AB

Telephone: +45 28 44 75 67                                                            Telephone: +45 40 15 66 69
E-mail: joo@synactpharma.com                                                     E-mail: tj@synactpharma.com